Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
Article
Psoriasis Drug MIA
San Francisco - The anti-CD40 ligand monoclonal antibody IDEC-131, manufactured by IDEC Pharmaceuticals, was developed to treat autoimmune and inflammatory diseases, such as psoriasis. IDEC-131 targets the CD40 ligand on T cells and regulates the interaction between T cells and B cells.
Related Videos
Related Content
